U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06960577) titled 'Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)' on April 29.
Brief Summary: The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Urinary Bladder Neoplasms
Immune Checkpoint Inhibitors
Methotrexate
Vinblastine
Doxorubicin
Cisplatin
Gemcitabine
Interv...